A phase IV trial to analyse the molecular prognostic factors for response to first-line treatment with bevacizumab and interferon in patients with advanced or metastatic renal cancer [Ensayo clinico fase IV.II para el analisis de los factores moleculares de pronostico de respuesta y beneficio clinico en pacientes con cancer renal metastasico o avanzado, tratados con bevacizumab e interferon como primera linea de tratamiento]

Trial Profile

A phase IV trial to analyse the molecular prognostic factors for response to first-line treatment with bevacizumab and interferon in patients with advanced or metastatic renal cancer [Ensayo clinico fase IV.II para el analisis de los factores moleculares de pronostico de respuesta y beneficio clinico en pacientes con cancer renal metastasico o avanzado, tratados con bevacizumab e interferon como primera linea de tratamiento]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2011

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms REVAMARK
  • Most Recent Events

    • 23 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top